Posted by Sherry C. on Friday, January 10th, 2014
Alzheimer’s disease doesn’t just affect the patient; it affects the entire family. Recently, the Alzheimer’s Prevention & Treatment Program (APTP) and Alzheimer’s Prevention Clinic (APC) at New York-Presbyterian / Weill Cornell Medical Center was founded by Neurologist Dr. Richard Isaacson, an Alzheimer’s specialist who has several family members with this disease. This specialized clinic and research program focuses on the latest treatments for patients, as well as cutting-edge strategies that may reduce a person’s risk for AD (or help to delay its onset), with an emphasis on nutritional approaches and comprehensive education for the entire family. Interested in scheduling a consultation? Please call 212-746-0226
Scientists now understand that AD starts in the brain 20 to 30 years before the onset of symptoms, giving physicians ample time to intervene in an individualized fashion for those as risk. There is no “magic pill” or “magic cure” for AD treatment or prevention; however, combining a variety of strategies based on strong science and safety may yield the best chance for benefit.
As a part of this initiative, individuals interested in lowering their risk for Alzheimer’s can be followed over time and receive a personalized plan based on a variety of elements, such as their risk factors, genes, past/present medical conditions, and the latest scientific research. Patients in the APTP and APC will be cared for over time using a sophisticated and interactive state-of-the-art research tool and database. This approach allows for ongoing monitoring and the development of personalized therapeutic options aimed at reducing Alzheimer’s disease risk and providing optimal care.
The approach is based on a collaborative care model for Alzheimer’s disease, while being firmly grounded in the latest scientific evidence-based therapies. This integrated approach to care aims to provide the most comprehensive therapies for patients with Alzheimer’s disease, mild cognitive impairment due to Alzheimer’s, “preclinical” Alzheimer’s, and patients who are at risk for the disease.
Or, Visit this Page to Learn More about the Personalized Approach at the APTP.